drugset / Trial / NCT04898283

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

NCT04898283 ↗

Phase 3 Recruiting 180 enrolled Inmunotek S.L.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitized to cupressaceae and grasses.

Timeline

Start
2021-05-31
Primary completion
2026-10
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MG01 Protein / enzyme biologic 10000 unknown Subcutaneous
Subject MG01 Protein / enzyme biologic 30000 unknown Subcutaneous
Subject T521 Unknown 10000 unknown Subcutaneous